뒤로
Dbv Technologies SA (DBVTF) 수입
DBVTF 주가 차트
DBVTF 수입
Dbv Technologies SA
$4.3
0%
$0
종가: Mar 24, 16:00:00 GMT-4
$4.3
0%
$0
애프터마켓: Mar 24, 20:00:00 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-10-28
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
DBVTF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Dbv Technologies SA DBVTF의 지난 분기 매출 실적은 어땠나요?
Dbv Technologies SA의 매출 추정치는 얼마인가요?
Dbv Technologies SA의 수익 품질 점수는 얼마인가요?
Dbv Technologies SA는 언제 수익을 보고하나요?
Dbv Technologies SA의 예상 수익은 얼마인가요?
Dbv Technologies SA은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$4.3
시가
$4.3
일일 범위
$4.3 - $4.3
52주 범위
$0.0001 - $4.79
거래량
100
평균 거래량
8
배당수익률
--
EPS(TTM)
-1.12
시가총액
$236.3M
DBV TECHNOLOGIES란 무엇인가요?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.